Heterogeneity of Treatment Effects: Implications for Guidelines, Payment, and Quality Assessment

American Journal of Medicine

Volumn 120, Issue 4 SUPPL., 2007, Pages

  Greenfield, Sheldon ^a   Kravitz, Richard ^b   Duan, Naihua ^c   Kaplan, Sherrie H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Health policy; Healthcare quality assurance; Heterogeneity; Population genetics; Practice guidelines

Indexed keywords

ARTICLE; CLINICAL RESEARCH; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; MEDICAL FEE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; CALIFORNIA; EVIDENCE-BASED MEDICINE; FEMALE; GENETICS, POPULATION; HEALTH POLICY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SELECTION; POLICY MAKING; PRACTICE GUIDELINES; PROSPECTIVE PAYMENT SYSTEM; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 33947617788     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.02.002     Document Type: Article

References (52)

1. Goldstein D.B. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 348 (2003) 553-556
2. Spear B.B., Heath-Chiozzi M., and Huff J. Clinical application of pharmacogenetics. Trends Mol Med 7 (2001) 201-204
3. Hayward R.A., Kent D.M., Vijan S., and Hofer T.P. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 6 (2006) 18
4. Kravitz R.L., Duan N., and Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82 (2004) 661-687
5. Bhatt D.L., Fox K.A., Hacke W., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
6. Terris S. Calcium plus vitamin D and the risk of fractures. N Engl J Med 354 (2006) 2285-2287
7. Clegg D.O., Reda D.J., Harris C.L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354 (2006) 795-808
8. Ernst E. Glucosamine and chondroitin sulfate for knee osteoarthritis. N Engl J Med 354 (2006) 2184-2185
9. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354 (2006) 669-683
10. Pfeffer M.A., and Jarcho J.A. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 354 (2006) 1744-1746
11. Brindis R.G., and Spertus J. The role of academic medicine in improving health care quality. Acad Med 81 (2006) 802-806
12. Pronovost P., Holzmueller C.G., Needham D.M., et al. How will we know patients are safer?. An organization-wide approach to measuring and improving safety. Crit Care Med 34 (2006) 1988-1995
13. Chassin M.R. Does paying for performance improve the quality of health care?. Med Care Res Rev 63 (2006) 122S-125S
14. Levenson S. "Pay for performance": can it help improve long-term care?. J Am Med Dir Assoc 7 (2006) 262-264
15. Goldfield N., Burford R., Averill R., et al. Pay for performance: an excellent idea that simply needs implementation. Qual Manag Health Care 14 (2005) 31-44
16. Petersen L.A., Woodard L.D., Urech T., Daw C., and Sookanan S. Does pay-for-performance improve the quality of health care?. Ann Intern Med 145 (2006) 265-272
17. Boyd C.M., Darer J., Boult C., et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294 (2005) 716-724
18. Tan K.B. Clinical practice guidelines: a critical review. Int J Health Care Qual Assur Inc Leadersh Health Serv 19 (2006) 195-220
19. Philips Z., Ginnelly L., Sculpher M., et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8 (2004) iii-xi 1
20. Jamtvedt G., Young J.M., Kristoffersen D.T., O'Brien M.A., and Oxman A.D. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2 (2006) CD000259
21. Frolich A., Talavera J.A., Broadhead P., and Adams D.R. A behavioral model of clinician responses to incentives to improve quality. Health Policy 80 (2007) 179-193
22. Albertsen P.C., Fryback D.G., Storer B.E., Kolon T.F., and Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274 (1995) 626-631
23. Litwin M.S., Greenfield S., Elkin E.P., et al. Assessment of prognosis with the Total Illness Burden Index for Prostate Cancer (TIBI-CaP): aiding clinicians in treatment choice (2006) Presented at the annual meeting of the American Urological Association, May 20; Atlanta, Georgia.
24. Greenfield S., Kaplan S.H., and Nicolucci A. The diabetes patient's "other" diseases lead to 5-year mortality (2006) Presented at the Midwest Society of General Internal Medicine, Quality Summit II. September 29; Chicago, Illinois.
25. Longford N.T. Selection bias and treatment heterogeneity in clinical trials. Stat Med 18 (1999) 1467-1474
26. Roses A.D. Pharmacogenetics and the practice of medicine. Nature 405 (2000) 857-865
27. Vijan S., Hofer T.P., and Hayward R.A. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 127 (1997) 788-795
28. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 2542-2551
29. Lip G.Y., and Lowe G.D. ABC of atrial fibrillation: antithrombotic treatment for atrial fibrillation. BMJ 312 (1996) 45-49
30. Hayward R.A., Kent D.M., Vijan S., and Hofer T.P. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) 24 (2005) 1571-1581
31. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 97 (2005) 412-413
32. Sindrup S.H., and Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5 (1995) 335-346
33. McCormick A.W., Whitney C.G., Farley M.M., et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 9 (2003) 424-430
34. Huppert J.D., Schultz L.T., Foa E.B., et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry 161 (2004) 1485-1487
35. Senn S. Individual response to treatment: is it a valid assumption?. BMJ 329 (2004) 966-968
36. Materson B.J. Variability in response to antihypertensive drugs. Am J Med 120 (2007) S10-S20
37. Carson III C.C. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 96 (2005) 37M-41M
38. Lassila H.C., Stoehr G.P., Ganguli M., et al. Use of prescription medications in an elderly rural population: the MoVIES Project. Ann Pharmacother 30 (1996) 589-595
39. Stoehr G.P., Ganguli M., Seaberg E.C., Echement D.A., and Belle S. Over-the-counter medication use in an older rural community: the MoVIES Project. J Am Geriatr Soc 45 (1997) 158-165
40. Routledge P.A., O'Mahony M.S., and Woodhouse K.W. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57 (2004) 121-126
41. Fortin M., Dionne J., Pinho G., et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities?. Ann Fam Med 4 (2006) 104-108
42. Rothwell P.M., Warlow C.P., and European Carotid Surgery Trialists' Collaborative Group. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet 353 (1999) 2105-2110
43. Kent D.M., Ruthazer R., and Selker H.P. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?. Stroke 34 (2003) 464-467
44. Pocock S.J., McCormack V., Gueyffier F., et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 323 (2001) 75-81
45. Slotman G.J. Prospectively validated prediction of organ failure and hypotension in patients with septic shock: the Systemic Mediator Associated Response Test (SMART). Shock 14 (2000) 101-106
46. Stier D.M., Greenfield S., Lubeck D.P., et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 54 (1999) 424-429
47. Zimmerman J.E., Wagner D.P., Draper E.A., et al. Evaluation of acute physiology and chronic health evaluation III predictions of hospital mortality in an independent database. Crit Care Med 26 (1998) 1317-1326
48. Selker H.P., Griffith J.L., Beshansky J.R., et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med 127 (1997) 538-556
49. Lagakos S.W. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354 (2006) 1667-1669
50. Kraemer H.C., and Kupfer D.J. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59 (2006) 990-996
51. Kraemer H.C., Frank E., and Kupfer D.J. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 296 (2006) 1286-1289
52. Vijan S., and Hayward R.A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138 (2003) 593-602